Virta Health
Nutrition-first diabetes and obesity reversal with explicit deprescribing goals
Founded 2014 · Denver, CO · Private · Website
Our verdict
The highest-conviction pick when your population fits. Nothing else here combines randomized evidence with fees genuinely at risk — but underwrite it on realistic enrollment, not on completer outcomes.
Scorecard
How it scored
Scored against the published rubric. Weights are fixed before review and identical for every vendor.
Prescriber credentials, titration protocol, comorbidity screening, and off-ramp planning.
Quality of published results: peer review, sample size, control group, and follow-up duration.
Ability to hold net pharmacy spend down: gating, biosimilar strategy, and risk sharing.
Eligibility-level reporting, claims feeds, and whether you can audit the vendor's own numbers.
PBM, carrier, HRIS, and point-solution interoperability without custom engineering.
Time to first appointment, app quality, care-team continuity, and support responsiveness.
Analysis
What we found
Virta is the strongest vendor in this evaluation on the two dimensions that survive CFO scrutiny — evidence quality and financial alignment. It is the only participant with multi-year randomized data, and it is willing to place effectively all of its fees at risk against clinical targets, which no other vendor here does. The strategic difference is philosophical: Virta treats a GLP-1 as an escalation, not a starting point, and measures itself on medication reduction. The constraint is reach. The protocol asks a great deal of members, and it only serves a diabetic-adjacent population.
Strengths
- The only vendor here with multi-year randomized evidence and independent replication
- Fee structure genuinely aligns with the buyer — Virta loses money when members do not improve
- Deprescribing focus means it is the rare vendor that can plausibly reduce total pharmacy spend rather than grow it
Limitations
- The nutritional protocol is demanding and self-selects; enrollment rates run below coaching-first vendors
- Requires a diabetes or prediabetes diagnosis, so it cannot serve a general weight-management population
- 36-month term and 2,000-life minimum put it out of reach for smaller employers
Best for
Self-insured employers with a diabetic or prediabetic population and a mandate to bend pharmacy trend downward.
Watch out
Enrollment is the whole risk. Model your results at realistic uptake, not at the enrolled-member outcomes in the sales deck.
The details
Commercial and clinical specifics
The facts you will need to build a comparison grid. Verify each against the vendor's own documentation before contracting.
Pricing
- Model
- Outcomes-based — substantial share of fees contingent on clinical results
- PMPM range
- $40–$95
- Setup fee
- None
- Medications included
- No
- Performance guarantees
- Up to 100% of fees at risk against A1c, weight, and medication-reduction targets
Contract
- Minimum lives
- 2,000
- Term
- 36 months
- Termination notice
- 120 days
Eligibility
- BMI threshold
- BMI ≥ 30, or type 2 diabetes / prediabetes at any BMI
- Prior authorization
- No
- Step therapy
- Yes
- Comorbidity required
- Yes
Clinical model
- Prescribes
- Yes
- Care team
- Physicians, Nurse practitioners, Health coaches, Registered dietitians
- Titration protocol
- Nutritional ketosis first; medication added only when nutrition alone misses targets
- Off-ramp
- Deprescribing is the stated clinical goal, with continuous medication-reduction tracking
- Formulary
- Semaglutide, Tirzepatide, Metformin, Insulin (reduction focus), SGLT2 inhibitors
Outcomes evidence
- Headline claim
- HbA1c reduced by 1.3 points at one year with 60% of retained patients below 6.5% without diabetes medication other than metformin, alongside 12% body-weight loss
- Evidence level
- Peer-reviewed observationalPublished cohort data, no randomization.
- Sample size
- Several hundred in the controlled study; larger registry cohorts reported separately
- Follow-up
- 1 year in the principal study, with 2- and 5-year follow-up published
Sources
- Hallberg SJ et al. Diabetes Therapy 2018;9(2):583–612Open-label, NON-randomised, controlled study — which is why this is not rated as an RCT
- Bhanpuri NH et al. Cardiovascular Diabetology 2018;17:56Cardiovascular risk factor outcomes at one year
- Virta Health research summaryCompany summary of the above, including 12% body-weight loss and class III obesity falling from 46% to 20%
Outcomes verified 2026-09-19. Pricing and contract figures on this page are category planning benchmarks, not vendor quotes — see methodology.
Integrations
- PBMs
- CVS Caremark, Express Scripts, Optum Rx
- Carriers
- Aetna, Cigna, UnitedHealthcare, BCBS plans
- HRIS
- Workday, ADP, UKG
- Eligibility file
- 834, weekly cadence
Formulary
Virta Health by medication
How a vendor positions each molecule reveals more about its cost discipline than any single score. First-line means an eligible member can start immediately; escalation means a documented lower-cost trial comes first.
Virta Health Reviews Semaglutide
GLP-1 receptor agonist
Positioned explicitly as an escalation, not a starting point. Nutritional ketosis is attempted first, and semaglutide is added only where nutrition alone misses clinical targets. Virta measures itself on medication reduction, so its incentives point away from initiating here.
Virta Health Reviews Tirzepatide
Dual GIP/GLP-1 receptor agonist
Same escalation-only posture as semaglutide. Virta is one of very few vendors here whose fee structure loses money when members remain on high-cost incretin therapy long term.
Virta Health Reviews Metformin
Biguanide
A core first-line agent, and one Virta actively works to deprescribe alongside insulin as nutritional response improves. Medication elimination is the stated clinical endpoint rather than a side effect.
Alternatives
Others in metabolic specialist
Same category, so these are genuine substitutes rather than different products at different prices.
Sensor-driven metabolic modeling aimed at medication reduction
- PMPM benchmark
- $55–$120
- Minimum lives
- 1,500
Virtual cardiometabolic clinic with bundled labs and pharmacy
- PMPM benchmark
- $34–$72
- Minimum lives
- 500